Only a clear understanding of the mechanisms leading to GLI activation in each tumour will allow for selection of the appropriate HH pathway inhibitor and, in cases where crosstalk between HH and other oncogenic pathways occurs, the optimal combinatorial partner. This evidence concerns the gene GLI1 and neoplasm.